SCHEMBL30765509

SCHEMBL30765509

CCCCOC(=O)Cn1c(N2CCOCC2)ncc(N[C@H](C)c2coc(-c3ccccc3)n2)c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.43
GAA P10253 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TSHR P16473 3/20 0.39
MAPT P10636 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
ADORA1 P30542 1/20 0.36
ALDH1A1 P00352 5/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
CASP1 P29466 2/20 0.36
HTT P42858 1/20 0.36
KDM4E B2RXH2 1/20 0.36
P2RY12 Q9H244 1/20 0.35
MAPK1 P28482 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
POLB P06746 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765552 0.88 LMNA (0.38) LMNAL3MBTL1ALDH1A1KDM4EMAPK1
SCHEMBL30766047 0.88 ALDH1A1 (0.35) LMNAL3MBTL1ALDH1A1CASP1KDM4E
SCHEMBL30765616 0.84 LMNA (0.37) LMNAGAAL3MBTL1TSHRMAPT
SCHEMBL30765924 0.82 GAA (0.45) LMNAGAAL3MBTL1TSHRMAPT
SCHEMBL30765621 0.81 GAA (0.42) LMNAGAAL3MBTL1TSHRMAPT
SCHEMBL30765811 0.81 L3MBTL1 (0.41) LMNAGAAL3MBTL1TSHRMAPT
SCHEMBL30765657 0.78 F2 (0.36) LMNAL3MBTL1MAPK1TP53
SCHEMBL30765996 0.76 MAPT (0.41) LMNAGAAL3MBTL1TSHRMAPT
SCHEMBL30766019 0.72 LMNA (0.54) LMNAGAAL3MBTL1TSHRMAPT
SCHEMBL30765532 0.71 GAA (0.53) GAAL3MBTL1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed